Patents Assigned to AB Science
-
Publication number: 20240058328Abstract: A 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of less severe and/or early-stage Alzheimer's disease in a patient in need thereof. In particular, masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of Alzheimer's disease in a patient having a baseline ADCS-ADL (Alzheimer's Disease Cooperative Study—Activities of Daily Living) score equal to or greater, preferably greater than 32, having a baseline MMSE (Mini-Mental State Examination) score equal to or greater than 13, having a time from diagnosis to treatment initiation with masitinib, or a pharmaceutically acceptable salt or solvate thereof, equal to or less than 5 years, and/or having a baseline ADAS-Cog (Alzheimer's Disease Assessment Scale—Cognitive Subscale) score equal to or lower than 40.Type: ApplicationFiled: December 16, 2021Publication date: February 22, 2024Applicant: AB SCIENCEInventors: Alain MOUSSY, Colin MANSFIELD
-
Publication number: 20230321081Abstract: Masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in a subject in need thereof. In particular, masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of mCRPC in a subject suffering from early mCRPC associated (i) with alkaline phosphatase (ALP) levels at baseline equal to or lower than 250 IU/L, or (ii) with a Halabi prognosis score (H) at baseline equal to or lower than 33, or (iii) with ALP levels at baseline equal to or lower than 250 IU/L and with a Halabi prognosis score (H) at baseline equal to or lower than 33.Type: ApplicationFiled: May 17, 2022Publication date: October 12, 2023Applicant: AB SCIENCEInventors: Alain MOUSSY, Colin MANSFIELD
-
Publication number: 20230226043Abstract: A method for the treatment of a coronavirus infection, such as a SARS-CoV-2 infection causing coronavirus disease 2019 (COVID-19), in a subject in need thereof, which includes the administration of masitinib, or a pharmaceutically acceptable salt or solvate thereof. In addition, at least one further pharmaceutically active agent may also be administered.Type: ApplicationFiled: April 9, 2021Publication date: July 20, 2023Applicants: AB SCIENCE, THE UNIVERSITY OF CHICAGOInventors: Alain MOUSSY, Savas TAY, Nir DRAYMAN, Glenn RANDALL, Siquan CHEN
-
Publication number: 20230089715Abstract: Masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of progressive multiple sclerosis (MS) in a patient who has a time from diagnosis to treatment initiation with masitinib, or the pharmaceutically acceptable salt or solvate thereof, greater than 2 years and/or has a time from onset to treatment initiation with masitinib, or the pharmaceutically acceptable salt or solvate thereof, greater than 5 years. In particular, masitinib, or the pharmaceutically acceptable salt or solvate thereof, is for use in the treatment of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (non-active SPMS) in a patient who has a time from diagnosis to treatment initiation with masitinib, or the pharmaceutically acceptable salt or solvate thereof, greater than 2 years and/or has a time from onset to treatment initiation with masitinib, or the pharmaceutically acceptable salt or solvate thereof, greater than 5 years.Type: ApplicationFiled: February 19, 2021Publication date: March 23, 2023Applicant: AB SCIENCEInventors: Alain MOUSSY, Colin MANSFIELD
-
Publication number: 20230023935Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of asthma in a subject in need thereof, wherein the subject has an elevated level of eosinophils. In particular, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of asthma in a subject with an eosinophil blood count at baseline ranging from 150 cells/?L to 300 cells/?L.Type: ApplicationFiled: December 2, 2020Publication date: January 26, 2023Applicant: AB SCIENCEInventors: Alain MOUSSY, Jean-Pierre KINET
-
Publication number: 20230000838Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.Type: ApplicationFiled: November 20, 2020Publication date: January 5, 2023Applicants: AB SCIENCE, UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADESInventors: Alain MOUSSY, Jean-Pierre KINET, Olivier HERMINE, Thiago TROVATI MACIEL, Slimane ALLALI, Rachel RIGNAULT-BRICARD, Caroline CARVALHO
-
Patent number: 10570122Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.Type: GrantFiled: February 5, 2016Date of Patent: February 25, 2020Assignee: AB ScienceInventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
-
Patent number: 10392373Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.Type: GrantFiled: September 16, 2016Date of Patent: August 27, 2019Assignee: AB ScienceInventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
-
Patent number: 10238649Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.Type: GrantFiled: October 4, 2013Date of Patent: March 26, 2019Assignee: AB SCIENCEInventors: Alain Moussy, Jean-Pierre Kinet
-
Patent number: 10202370Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.Type: GrantFiled: June 20, 2014Date of Patent: February 12, 2019Assignee: AB SCIENCEInventors: Alain Moussy, Abdellah Benjahad, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Jason Martin, Willy Picoul
-
Patent number: 10092564Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.Type: GrantFiled: March 24, 2017Date of Patent: October 9, 2018Assignee: AB SCIENCEInventors: Alain Moussy, Jean-Pierre Kinet, Colin Mansfield
-
Patent number: 10053455Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.Type: GrantFiled: March 23, 2015Date of Patent: August 21, 2018Assignee: AB SCIENCEInventors: Abdellah Benjahad, Jason Martin, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Willy Picoul, Alain Moussy
-
Patent number: 10045978Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.Type: GrantFiled: December 2, 2015Date of Patent: August 14, 2018Assignee: AB SCIENCEInventors: Alain Moussy, Jean-Pierre Kinet
-
Publication number: 20170340629Abstract: Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent.Type: ApplicationFiled: December 15, 2015Publication date: November 30, 2017Applicant: AB SCIENCEInventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
-
Publication number: 20160244845Abstract: An in vitro method for determining the prognosis of pancreatic cancer in a patient includes the following steps: a) measuring the expression level of at least one gene chosen from the group consisting of: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of the patient, b) predicting the outcome of the pancreatic cancer in the patient. a kit specifically designed to carry out such a method is also described.Type: ApplicationFiled: October 3, 2014Publication date: August 25, 2016Applicants: AB Science, ACOBIOMInventors: David PIQUEMAL, Alain MOUSSY, Jean-Pierre KINET
-
Patent number: 9168245Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.Type: GrantFiled: July 24, 2012Date of Patent: October 27, 2015Assignee: AB SCIENCEInventors: Abdellah Benjahad, Alain Moussy, Emmanuel Chevenier, Willy Picoul, Anne Lermet, Didier Pez, Jason Martin, Franck Sandrinelli
-
Publication number: 20150272945Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.Type: ApplicationFiled: October 4, 2013Publication date: October 1, 2015Applicant: AB SCIENCEInventors: Alain Moussy, Jean-Pierre Kinet, David Piquemal
-
Patent number: 9078894Abstract: The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 3, 2012Date of Patent: July 14, 2015Assignee: AB SCIENCEInventors: Alain Moussy, Jean-Pierre Kinet
-
Patent number: 8993573Abstract: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.Type: GrantFiled: November 26, 2013Date of Patent: March 31, 2015Assignee: AB ScienceInventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy
-
Patent number: 8962665Abstract: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.Type: GrantFiled: January 12, 2011Date of Patent: February 24, 2015Assignee: AB ScienceInventors: Alain Moussy, Abdellah Benjahad, Jason Martin, Emmanuel Chevenier, Didier Pez, Franck Sandrinelli, Willy Picoul